CD38 as an immunotherapeutic target in multiple myeloma.

Francesca BonelloMattia D'AgostinoMaria MoscvinChiara CerratoMario BoccadoroFrancesca Gay

Published in: Expert opinion on biological therapy (2018)

Monoclonal antibodies (mAbs) targeting CD38 are currently changing the treatment scenario in MM, allowing physicians to reach unprecedented results, especially when anti-CD38 mAbs are used in combination with consolidated MM treatments. Other immunotherapies targeting CD38 - such as conjugated anti-CD38 mAbs, bispecific antibodies stimulating T cells to eliminate CD38+ MM cells, and CD38-specific chimeric antigen receptor T cells - are interesting strategies, currently at earlier developmental stages.

Keyphrases

nk cells
multiple myeloma
induced apoptosis
photodynamic therapy
cell proliferation
combination therapy
pi k akt